Medicine:D-glycerate dehydrogenase deficiency
| D-glycerate dehydrogenase deficiency | |
|---|---|
| Other names | 3-phosphoglycerate dehydrogenase deficiency, PHGDH deficiency, PHGDHD |
 | |
| Condition is acquired via an autosomal recessive pattern | |
| Specialty | Metabolism |
| Symptoms | Congenital microcephaly, psychomotor retardation and seizures in infants, moderate developmental delay and behavioral disorders juveniles.[1] |
| Usual onset | Adolescent, Infancy, Childhood |
| Causes | Genetic |
| Prevention | N/A |
| Treatment | Diet |
| Medication | Serine |
| Prognosis | Shortened life expectancy |
| Frequency | <1 / 1 000 000 |
D-glycerate dehydrogenase deficiency (or 3-phosphoglycerate dehydrogenase deficiency, PHGDH deficiency, PHGDHD) is a rare autosomal metabolic disease where the young patient is unable to produce an enzyme necessary to convert 3-phosphoglycerate into 3-phosphohydroxypyruvate, which is the only way for humans to synthesize serine.This disorder is called Neu–Laxova syndrome in neonates.
Symptoms and signs
In addition significantly shortening lifespan, PHGDH deficiencies are known to cause congenital microcephaly, psychomotor retardation, and seizures in both humans and rats, presumably due to the essential signaling within the nervous system that serine, glycine, and other downstream molecules are intimately involved with.[citation needed]
Cause
Homozygous or compound heterozygous mutations in 3-phosphoglycerate dehydrogenase (PHGDH) cause Neu-Laxova syndrome[2][3] and phosphoglycerate dehydrogenase deficiency.[4]
Mechanism
3-Phosphoglycerate dehydrogenase catalyzes the transition of 3-phosphoglycerate into 3-phosphohydroxypyruvate, which is the committed step in the phosphorylated pathway of L-serine biosynthesis. It is also essential in cysteine and glycine synthesis, which lie further downstream.[5] This pathway represents the only way to synthesize serine in most organisms except plants, which uniquely possess multiple synthetic pathways. Nonetheless, the phosphorylated pathway that PHGDH participates in is still suspected to have an essential role in serine synthesis used in the developmental signaling of plants.[6][7]
Diagnosis
Treatment
Treatment typically involves oral supplementation of serine and glycine.[8][9]
References
- ↑ "Orphanet: Search by disease name". https://www.orpha.net/consor/cgi-bin/Disease_Search_Simple.php?lng=EN.
- ↑ "Neu-Laxova syndrome, an inborn error of serine metabolism, is caused by mutations in PHGDH". American Journal of Human Genetics 94 (6): 898–904. Jun 2014. doi:10.1016/j.ajhg.2014.04.015. PMID 24836451.
- ↑ "Neu-Laxova syndrome is a heterogeneous metabolic disorder caused by defects in enzymes of the L-serine biosynthesis pathway". American Journal of Human Genetics 95 (3): 285–93. Sep 2014. doi:10.1016/j.ajhg.2014.07.012. PMID 25152457.
- ↑ "3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis". Archives of Disease in Childhood 74 (6): 542–5. Jun 1996. doi:10.1136/adc.74.6.542. PMID 8758134.
- ↑ "MetaCyc L-serine biosynthesis". http://biocyc.org/META/NEW-IMAGE?type=PATHWAY&object=SERSYN-PWY.
- ↑ "Serine in plants: biosynthesis, metabolism, and functions". Trends in Plant Science 19 (9): 564–9. Sep 2014. doi:10.1016/j.tplants.2014.06.003. PMID 24999240.
- ↑ "Regulation of serine biosynthesis in Arabidopsis. Crucial role of plastidic 3-phosphoglycerate dehydrogenase in non-photosynthetic tissues". The Journal of Biological Chemistry 274 (1): 397–402. Jan 1999. doi:10.1074/jbc.274.1.397. PMID 9867856.
- ↑ "Beneficial effects of L-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency". Annals of Neurology 44 (2): 261–5. Aug 1998. doi:10.1002/ana.410440219. PMID 9708551.
- ↑ "Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency". Lancet 364 (9452): 2221–2. 2004-12-18. doi:10.1016/S0140-6736(04)17596-X. PMID 15610810.
External links
| Classification |
|---|
 |  |
